NPPB and hydrops fetalis: For instance, in the PROVE-HF study by Januzzi et al., patients receiving SV had an LVEF increase from 28.2% to 37.8% and a median NT-proBNP reduction from 816 pg/mL to 455 pg/mL over 12 months, highlighting the therapy’s favorable effects on cardiac remodeling [15].